Gilead Sciences (NASDAQ:GILD) Stock Rating Reaffirmed by Oppenheimer

Oppenheimer restated their outperform rating on shares of Gilead Sciences (NASDAQ:GILD) in a report released on Friday morning, Benzinga reports. They currently have a $105.00 price objective on the biopharmaceutical company’s stock.

A number of other analysts have also weighed in on the stock. StockNews.com raised shares of Gilead Sciences from a buy rating to a strong-buy rating in a research note on Tuesday, March 26th. Royal Bank of Canada decreased their price target on Gilead Sciences from $76.00 to $75.00 and set a sector perform rating for the company in a research note on Wednesday, February 14th. UBS Group dropped their price objective on Gilead Sciences from $81.00 to $75.00 and set a neutral rating on the stock in a research note on Wednesday, April 17th. Truist Financial cut Gilead Sciences from a buy rating to a hold rating and decreased their target price for the company from $91.00 to $82.00 in a research note on Thursday, February 22nd. Finally, Wells Fargo & Company dropped their price target on shares of Gilead Sciences from $84.00 to $77.00 and set an equal weight rating on the stock in a research report on Monday, March 4th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of Hold and a consensus target price of $84.71.

Gilead Sciences Stock Up 0.9 %

Shares of Gilead Sciences stock opened at $66.76 on Friday. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.43 and a quick ratio of 1.27. Gilead Sciences has a 1-year low of $65.90 and a 1-year high of $87.86. The business’s fifty day moving average price is $71.96 and its two-hundred day moving average price is $76.57. The company has a market capitalization of $83.12 billion, a P/E ratio of 14.84, a PEG ratio of 0.92 and a beta of 0.19.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, February 6th. The biopharmaceutical company reported $1.72 earnings per share for the quarter, missing analysts’ consensus estimates of $1.76 by ($0.04). The company had revenue of $7.12 billion for the quarter, compared to the consensus estimate of $7.10 billion. Gilead Sciences had a net margin of 20.89% and a return on equity of 38.85%. Gilead Sciences’s revenue for the quarter was down 3.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.67 earnings per share. As a group, research analysts forecast that Gilead Sciences will post 6.55 EPS for the current year.

Gilead Sciences Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, March 28th. Shareholders of record on Friday, March 15th were issued a $0.77 dividend. This represents a $3.08 annualized dividend and a dividend yield of 4.61%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.75. The ex-dividend date of this dividend was Thursday, March 14th. Gilead Sciences’s dividend payout ratio (DPR) is presently 68.44%.

Insider Transactions at Gilead Sciences

In related news, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $73.18, for a total value of $146,360.00. Following the completion of the sale, the insider now owns 100,936 shares in the company, valued at approximately $7,386,496.48. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.16% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Norges Bank purchased a new position in Gilead Sciences during the 4th quarter valued at about $1,301,624,000. Arrowstreet Capital Limited Partnership boosted its holdings in shares of Gilead Sciences by 324.8% during the first quarter. Arrowstreet Capital Limited Partnership now owns 18,002,214 shares of the biopharmaceutical company’s stock worth $1,070,232,000 after purchasing an additional 13,764,169 shares during the period. Moneta Group Investment Advisors LLC grew its position in Gilead Sciences by 96,759.8% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 10,111,194 shares of the biopharmaceutical company’s stock valued at $868,046,000 after purchasing an additional 10,100,755 shares in the last quarter. Renaissance Technologies LLC increased its stake in Gilead Sciences by 70.6% in the 1st quarter. Renaissance Technologies LLC now owns 15,492,116 shares of the biopharmaceutical company’s stock valued at $921,006,000 after buying an additional 6,410,047 shares during the period. Finally, The Manufacturers Life Insurance Company lifted its position in Gilead Sciences by 78.8% in the 4th quarter. The Manufacturers Life Insurance Company now owns 7,632,000 shares of the biopharmaceutical company’s stock worth $618,268,000 after buying an additional 3,362,505 shares in the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.